Zeitschriftenartikel (19)

Dominguez-Meijide, A.; Vasili, E.; König, A.; Cima-Omori, M.-S.; Ibáñez de Opakua, A.; Leonov, A.; Ryazanov, S.; Zweckstetter, M.; Griesinger, C.; Outeiro, T. F.: Effects of pharmacological modulators of α-synuclein and tau aggregation and internalization. Scientific Reports 10, 12827 (2020)
Maurer, A.; Leonov, A.; Ryazanov, S.; Herfert, K.; Kuebler, L.; Buss, S.; Schmidt, F.; Weckbecker, D.; Linder, R.; Bender, D. et al.; Giese, A.; Pichler, B. J.; Griesinger, C.: 11 C radiolabeling of anle253b: A putative PET tracer for Parkinson's disease that binds to α-synuclein fibrils in vitro and crosses the blood-brain barrier. ChemMedChem 15 (5), S. 411 - 415 (2020)
Camilleri, A.; Ghio, S.; Caruana, M.; Weckbecker, D.; Schmidt, F.; Kamp, F.; Leonov, A.; Ryazanov, S.; Griesinger, C.; Giese, A. et al.; Cauchi, R. J.; Vassallo, N.: Tau-induced mitochondrial membrane perturbation is dependent upon cardiolipin. Biochimica et Biophysica Acta. Biomembranes 1862 (2), 183064 (2020)
Saravanan, M. S.; Ryazanov, S.; Leonov, A.; Nicolai, J.; Praest, P.; Giese, A.; Winter, R.; Khemtemourian, L.; Griesinger, C.; Killian, J. A.: The small molecule inhibitor anle145c thermodynamically traps human islet amyloid peptide in the form of non-cytotoxic oligomers. Scientific Reports 9 (1), 19023 (2019)
Wegrzynowicz, M.; Bar-On, D.; Calo’, L.; Anichtchik, O.; Iovino, M.; Xia, J.; Ryazanov, S.; Leonov, A.; Giese, A.; Dalley, J. W. et al.; Griesinger, C.; Ashery, U.; Spillantini, M. G.: Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model. Acta Neuropathologica 138 (4), S. 575 - 595 (2019)
Brendel, M.; Deussing, M.; Blume, T.; Kaiser, L.; Probst, F.; Overhoff, F.; Peters, F.; von Ungern-Sternberg, B.; Ryazanov, S.; Leonov, A. et al.; Griesinger, C.; Zwergal, A.; Levin, J.; Bartenstein, P.; Yakushev, I.; Cumming, P.; Boening, G.; Ziegler, S.; Herms, J.; Giese, A.; Rominger, A.: Late-stage Anle138b treatment ameliorates tau pathology and metabolic decline in a mouse model of human Alzheimer's disease tau. Alzheimer's Research and Therapy 11 (1), 67 (2019)
Bartels, M.; Weckbecker, D.; Kuhn, P. H.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Lichtenthaler, S. F.; Bötzel, K.; Giese, A.: Iron-mediated aggregation and toxicity in a novel neuronal cell culture model with inducible alpha-synuclein expression. Scientific Reports 9, 9100 (2019)
Heras‐Garvin, A.; Weckbecker, D.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.; Wenning, G. K.; Stefanova, N.: Anle138b modulates α-synuclein oligomerization and prevents motor decline and neurodegeneration in a mouse model of multiple system atrophy. Movement Disorders 34 (2), S. 255 - 263 (2019)
Ghio, S.; Camilleri, A.; Caruana, M.; Ruf, V. C.; Schmidt, F.; Leonov, A.; Ryazanov, S.; Griesinger, C.; Cauchi, R. J.; Kamp, F. et al.; Giese, A.; Vassallo, N.: Cardiolipin promotes pore-forming activity of alpha-synuclein oligomers in mitochondrial membranes. ACS Chemical Neuroscience 10 (8), S. 3815 - 3829 (2019)
Reiner, A. M.; Schmidt, F.; Ryazanov, S.; Leonov, A.; Weckbecker, D.; Deeg, A. A.; Griesinger, C.; Giese, A.; Zinth, W.: Photophysics of diphenyl-pyrazole compounds in solutions and α-synuclein aggregates. Biochimica et Biophysica Acta (BBA) - General Subjects 1862 (4), S. 800 - 807 (2018)
Martinez Hernandez, A.; Urbanke, H.; Gillman, A. L.; Lee, J.; Ryazanov, S.; Agbemenyah, H. Y.; Benito, E.; Jain, G.; Kaurani, L.; Grigorian, G. et al.; Leonov, A.; Rezaei-Ghaleh, N.; Wilken, P.; Arce, F. T.; Wagner, J.; Fuhrman, M.; Caruana, M.; Camilleri, A.; Vassallo, N.; Zweckstetter, M.; Benz, R.; Giese, A.; Schneider, A.; Korte, M.; Lal, R.; Griesinger, C.; Eichele, G.; Fischer, A.: The diphenylpyrazole compound anle138b blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology. EMBO Molecular Medicine 10 (1), S. 32 - 47 (2018)
Turriani, E.; Lázaro, D. F.; Ryazanov, S.; Leonov, A.; Giese, A.; Schön, M.; Schön, M. P.; Griesinger, C.; Outeiro, T. F.; Arndt-Jovin, D. J. et al.; Becker, D.: Treatment with diphenyl–pyrazole compound anle138b/c reveals that α-synuclein protects melanoma cells from autophagic cell death. Proceedings of the National Academy of Sciences of the United States of America 114 (25), S. E4971 - E4977 (2017)
Draycheva, A.; Bornemann, T.; Ryazanov, S.; Lakomek, N. A.; Wintermeyer, W.: The bacterial SRP receptor, FtsY, is activated on binding to the translocon. Molecular Microbiology 102 (1), S. 152 - 167 (2016)
Fellner, L.; Kuzdas-Wood, D.; Levin, J.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.; Wenning, G. K.; Stefanova, N.: Anle138b partly ameliorates motor deficits despite failure of neuroprotection in a model of advanced multiple system atrophy. Frontiers in Neuroscience 10, 99 (2016)
Wagner, J.; Krauss, S.; Shi, S.; Ryazanov, S.; Steffen, J.; Miklitz, C.; Leonov, A.; Kleinknecht, A.; Göricke, B.; Weishaupt, J. H. et al.; Weckbecker, D.; Reiner, A. M.; Zinth, W.; Levin, J.; Ehninger, D.; Remy, S.; Kretzschmar, H. A.; Griesinger, C.; Giese, A.; Fuhrmann, M.: Reducing tau aggregates with anle138b delays disease progression in a mouse model of tauopathies. Acta Neuropathologica 130 (5), S. 619 - 631 (2015)
Deeg, A. A.; Reiner, A. M.; Schmidt, F.; Schueder, F.; Ryazanov, S.; Ruf, V. C.; Giller, K.; Becker, S.; Leonov, A.; Griesinger, C. et al.; Giese, A.; Zinth, W.: Anle138b and related compounds are aggregation specific fluorescence markers and reveal high affinity binding to α-synuclein aggregates. Biochimica et Biophysica Acta-General Subjects 1850 (9), S. 1884 - 1890 (2015)
Shi, S.; Wagner, J.; Mitteregger-Kretzschmar, G.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.: Quantitative real-time quaking-induced conversion allows monitoring of disease-modifying therapy in the urine of prion-infected mice. Journal of Neuropathology and Experimental Neurology 74 (9), S. 924 - 933 (2015)
Levin, J.; Schmidt, F.; Boehm, C.; Prix, C.; Bötzel, K.; Ryazanov, S.; Leonov, A.; Griesinger, C.; Giese, A.: The oligomer modulator anle138b inhibits disease progression in a Parkinson mouse model even with treatment started after disease onset. Acta Neuropathologica 127 (5), S. 779 - 780 (2014)
Wagner, J.; Ryazanov, S.; Leonov, A.; Levin, J.; Shi, S.; Schmidt, F.; Prix, C.; Pan-Montojo, F.; Bertsch, U.; Mitteregger-Kretzschmar, G. et al.; Geissen, M.; Eiden, M.; Leidel, F.; Hirschberger, T.; Deeg, A. A.; Krauth, J.; Zinth, W.; Tavan, P.; Pilger, J.; Zweckstetter, M.; Frank, T.; Baehr, M.; Weishaupt, J. H.; Uhr, M.; Urlaub, H.; Teichmann, U.; Samwer, M.; Bötzel, K.; Groschup, M.; Kretzschmar, H.; Griesinger, C.; Giese, A.: Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease. Acta Neuropathologica 125 (6), S. 795 - 813 (2013)

Konferenzbeitrag (7)

Buss, S.; Kuebler, L.; Maurer, A.; Schmidt, F.; Leonov, A.; Ryazanov, S.; Giese, A.; Griesinger, C.; Pichler, B. J.; Herfert, K.: In vitro evaluation of small molecule compounds as potential PET tracers targeting a-synuclein. 29th International Symposium on Cerebral Blood Flow, Metabolism and Function / 14th International Conference on Quantification of Brain Function with PET (BRAIN and BRAIN Pet), Yokohama, Japan, 04. Juli 2019 - 07. Juli 2019. Journal of Cerebral Blood Flow and Metabolism 39 (Suppl), S. 530 - 531 (2019)
Zur Redakteursansicht